Cargando…
Lipid disorders /
Lipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key ther...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Oxford :
Clinical,
2009.
|
| Colección: | Therapeutic strategies.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | EBSCO_ocn666931928 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 100929s2009 enka ob 001 0 eng d | ||
| 040 | |a IDEBK |b eng |e pn |c IDEBK |d N$T |d EBLCP |d OCLCQ |d YDXCP |d OCLCQ |d MHW |d OCLCF |d UKDOC |d OCLCQ |d NLGGC |d OCLCQ |d D6H |d AGLDB |d Z5A |d OCLCQ |d VTS |d TOF |d AU@ |d JBG |d WYU |d STF |d M8D |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d UKAHL |d OCLCQ |d OCLCO |d SGP |d OCL |d OCLCQ | ||
| 019 | |a 416480892 |a 815776118 |a 965934893 | ||
| 020 | |a 9781846926013 |q (electronic bk.) | ||
| 020 | |a 1846926017 |q (electronic bk.) | ||
| 020 | |a 1282093916 | ||
| 020 | |a 9781282093911 | ||
| 020 | |a 9781846920349 | ||
| 020 | |a 1846920345 | ||
| 029 | 1 | |a AU@ |b 000051378789 | |
| 029 | 1 | |a AU@ |b 000058165003 | |
| 029 | 1 | |a AU@ |b 000059216449 | |
| 029 | 1 | |a AU@ |b 000060067430 | |
| 029 | 1 | |a DEBBG |b BV043074194 | |
| 029 | 1 | |a DEBSZ |b 421988401 | |
| 029 | 1 | |a NZ1 |b 13545792 | |
| 035 | |a (OCoLC)666931928 |z (OCoLC)416480892 |z (OCoLC)815776118 |z (OCoLC)965934893 | ||
| 050 | 4 | |a RC632.L5 |b T66 2009 | |
| 060 | 4 | |a WD 200.5.H8 |b L762 2009 | |
| 072 | 7 | |a MED |x 027000 |2 bisacsh | |
| 072 | 7 | |a MED |x 060000 |2 bisacsh | |
| 072 | 7 | |a K |2 bicssc | |
| 082 | 0 | 4 | |a 616.3997 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Lipid disorders / |c edited by Andrew M. Tonkin ; foreword by Eugene Braunwald. |
| 246 | 1 | 4 | |a Therapeutic strategies in lipid disorders |
| 260 | |a Oxford : |b Clinical, |c 2009. | ||
| 300 | |a 1 online resource (ix, 284 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Therapeutic strategies | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a Lipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key therapeutic target for clinicians. This book examines the causes and consequences of lipid disorders, and the treatments available. Special chapters are dedicated to the associations between lipid disorders and other conditions, for example cerebrovascular disease and heart failure, as well as the wider. | ||
| 505 | 0 | |a Editorand Contributors; Foreword; Chapter 1: A global view of cardiovascular risk factors; Chapter 2: Low-density lipoprotein cholesterol as a therapeutic target; Chapter 3: High-density lipoprotein as a therapeutic target; Chapter 4: Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias; Chapter 5: Management of coronary heart disease patients; Chapter 6: Stroke and transient ischaemic attack prevention; Chapter 7: Diabetes and the metabolic syndrome; Chapter 8: Hypertension; Chapter 9: Treatment of familial hypercholesterolaemia. | |
| 505 | 8 | |a Chapter 10: Lipid lowering in chronic kidney diseaseChapter 11: Statins and heart failure; Chapter 12: Absolute risk assessment in the general population; Chapter 13: Pleiotropic effects of statins and potential new indications; Chapter 14: The role of imaging endpoints in clinical trials; Chapter 15: Biomarkers in cardiovascular disease; Chapter 16: Novel lipid-modifying agents; Chapter 17: The enhanced evidence base and translation into improved outcomes; Abbreviations; Index. | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Lipids |x Metabolism |x Disorders. | |
| 650 | 0 | |a Lipids |x Metabolism. | |
| 650 | 2 | |a Dyslipidemias |x therapy | |
| 650 | 2 | |a Lipid Metabolism | |
| 650 | 6 | |a Lipides |x Métabolisme. | |
| 650 | 7 | |a MEDICAL |x Endocrinology & Metabolism. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nutrition. |2 bisacsh | |
| 650 | 7 | |a Lipids |x Metabolism. |2 fast |0 (OCoLC)fst00999374 | |
| 650 | 7 | |a Lipids |x Metabolism |x Disorders. |2 fast |0 (OCoLC)fst00999375 | |
| 700 | 1 | |a Tonkin, Andrew M. | |
| 776 | 0 | 8 | |i Print version: |t Lipid disorders. |d Oxford : Clinical, 2009 |z 9781846920349 |w (OCoLC)421776965 |
| 830 | 0 | |a Therapeutic strategies. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=277322 |z Texto completo |
| 938 | |a 123Library |b 123L |n 1866 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH28329618 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL434065 | ||
| 938 | |a EBSCOhost |b EBSC |n 277322 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 209391 | ||
| 938 | |a YBP Library Services |b YANK |n 3032031 | ||
| 994 | |a 92 |b IZTAP | ||